Docetaxel (DTX) is used for the treatment of advanced hormone refractory prostate cancer. Connexin 43 (Cx43) is a tumor suppressor gene, and transfection of the Cx43 gene increases sensitivity to several chemotherapeutic agents. The objective of this study was to evaluate the effectiveness of combination therapy of Cx43-expressing plasmid DNA (pCMV-Cx43) and DTX both in vitro and in vivo using ...

background: androgen receptors (ar) play an important role in proliferation of cancerous prostatic cells and prevention of apoptotic signaling. current drugs cannot inhibit the activity of these receptors very well. establishment of appropriate animal models is essential for discovery of new drugs of target therapy in hormone dependent prostate cancer. materials and methods: standard prostatic ...

During the last decade, transient receptor potential (TRP) channels emerge as key proteins in central mechanisms of the carcinogenesis such as cell proliferation, apoptosis and migration. Initial studies showed that expression profile of some TRP channels, notably TRP melastatin 8 (TRPM8), TRP vanilloid 6 (TRPV6),TRP canonical (TRPC6) and TRPV2, is changing during the development and the progre...

Objectives: Bone metastases develop in the majority of patients with advanced prostate cancer, and this fact puts these patients at high risk for potentially debilitating skeletal complications. Emerging therapies for the prevention of these complications are important for preserving patients’ quality of life. Methods: Existing and novel therapies were identified and researched through PubMed a...

Although many treatments have been applied to treat hormone-refractory prostate cancer (HRPC), therapeutic outcome is not altogether satisfactory. In the case of locally recurring HRPC, uncontrolled gross hematuria, dysuria, and scalding are often experienced. We report a patient who improved following intra-arterial infusion of cisplatin (CDDP) and ifosfamide (IFM) to treat urinary retention c...